CVS Shares Plunge as Volume Surges 151.98% to Rank 106th Amid Silent Guidance on Medicare Ratings

On September 8, 2025, , . The drop followed a private investor presentation hosted by Morgan Stanley, where executives offered no clarity on upcoming government quality ratings or financial guidance.

During the session, CEO David Joyner and CFO Brian Newman declined to address potential changes in Medicare Advantage Star ratings, which directly impact revenue from Aetna’s insurance operations. These ratings, determining reimbursement levels for Medicare and prescription drug plans, are typically released in the fall but remain unannounced this year. Executives noted the stock’s intraday decline but reiterated a policy of avoiding guidance between quarterly earnings reports, citing confidence in long-term performance despite near-term volatility.

Investors remain cautious as Star ratings carry significant weight for CVS’s Aetna division, which relies on favorable government assessments to maintain profitability. The lack of transparency from management has amplified uncertainty, particularly amid broader scrutiny of regulatory compliance and operational risks. However, .

I can help evaluate strategies using the current back-testing engine, which supports single-ticker analysis. For cross-sectional approaches like “top-500-by-volume,” alternatives include proxying with indices, narrowing to individual high-volume stocks, or exporting data for external analysis. Let me know how to proceed.